Global Ranitidine Market (2026-2031) - Rising Prevalence of Gastroesophageal Reflux Disease and Peptic Ulcers Drives Growth
Dublin, Aug. 25, 2026 (GLOBE NEWSWIRE) -- The "Ranitidine - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)" has been added to ResearchAndMarkets.com's offering.
Global Ranitidine Market Forecast to Reach USD 762.99 Million by 2031
The global ranitidine market is projected to increase from USD 589.15 million in 2025 to USD 613.13 million in 2026. It is forecast to reach USD 762.99 million by 2031, expanding at a compound annual growth rate of 4.47% between 2026 and 2031. Market growth is supported by the rising prevalence of gastroesophageal reflux disease (GERD) and peptic ulcer disease, continued demand for affordable acid-suppression therapies, and the introduction of reformulated products with enhanced impurity controls.
Rising GERD and Peptic Ulcer Burden Supports Ranitidine Market Growth
The increasing global burden of GERD and ulcer-related conditions continues to expand the addressable patient population. Global GERD prevalence rose at an average annual rate of 3.4% from 1990, reaching approximately 825.6 million prevalent cases in 2021. India recorded 36.6 million incident cases during that year, while China reported 20.9 million.
These high patient volumes are particularly relevant in price-sensitive healthcare markets, where treatment affordability and limited reimbursement influence prescribing and purchasing decisions. Demand for lower-cost acid-suppression therapies is expected to remain resilient across parts of Asia-Pacific, Africa, and South America, especially among uninsured and underinsured patients.
Established pharmaceutical manufacturing clusters in India also support the production and export of active pharmaceutical ingredients and finished dosage forms. Government incentives introduced in 2025 to encourage domestic production of essential pharmaceutical ingredients are expected to reinforce this supply base and improve access to affordable products in emerging markets.
Impurity Controls and Patient Confidence Remain Critical
The legacy of the 2020 ranitidine withdrawal in the United States continues to affect prescriber and patient confidence. Although reformulated ranitidine tablets received U.S. regulatory approval in 2025, market re-adoption is expected to be gradual because many patients have transitioned to famotidine or proton pump inhibitor therapies.
Manufacturers must demonstrate that reformulated ranitidine products can control N-nitrosodimethylamine risks throughout their shelf life. Enhanced testing, batch-release procedures, packaging requirements, and storage controls add complexity and cost, particularly for companies supplying tightly regulated markets. Consistent product quality and supporting evidence will be essential to rebuilding trust and enabling broader adoption.
150 mg Tablets Maintain the Leading Market Position
The 150 mg strength accounted for 48.71% of the ranitidine market in 2025, supported by its established role in outpatient GERD treatment and maintenance therapy for peptic ulcer disease. Hospitals and retail pharmacies commonly recognize this dosage as a standard prescription option where ranitidine remains authorized.
The 300 mg segment is forecast to record a 6.16% CAGR from 2026 through 2031. This strength supports single bedtime dosing protocols for selected patients with duodenal ulcers and may improve adherence in institutional settings where medication schedules are closely managed. Regulatory approval of reformulated 150 mg and 300 mg tablets in the United States has reopened access to two commercially significant strengths.
Tablets represented 61.82% of the market in 2025 due to their convenience, established prescribing history, and broad suitability for outpatient and hospital dispensing. Liquid formulations continue to serve pediatric patients, older adults, and individuals who experience difficulty swallowing tablets. The availability of multiple dosage forms remains important for addressing varied clinical and patient requirements.
Injectable ranitidine is projected to expand at a 4.82% CAGR between 2026 and 2031. Intravenous administration supports selected hospital applications, including stress ulcer prophylaxis, aspiration-risk management before anesthesia, and treatment for patients unable to receive oral medication. Demand is expected to remain concentrated in carefully managed acute-care settings.
North America Leads as Asia-Pacific Records the Fastest Growth
North America held 38.23% of the global ranitidine market in 2025 and retained the leading regional position in 2026. The approval of reformulated tablets restored prescription access in the United States following the earlier withdrawal. However, recovery is likely to remain measured because of prescription restrictions, storage requirements, continued safety monitoring, and the established use of alternative therapies.
Europe remains constrained by differing national regulatory policies and the continuing European Union suspension of ranitidine medicines. Acid-suppression treatment across the region has largely shifted toward proton pump inhibitors and famotidine. Any future market activity will depend on national authorization pathways, supply availability, and compliance with stringent impurity-control requirements.
Asia-Pacific is forecast to be the fastest-growing regional ranitidine market, registering a 5.29% CAGR through 2031. Growth is supported by high GERD incidence in India and China, extensive pharmaceutical manufacturing capacity, and demand for cost-effective generic medicines. India's bulk-drug production infrastructure is also positioned to supply domestic and international formulation markets.
Demand across the Middle East, Africa, and South America is expected to remain linked to affordable generic supply and public healthcare procurement. Indian manufacturers continue to serve many of these markets, while countries such as Brazil and Argentina maintain public-formulary demand under strengthened nitrosamine monitoring requirements.
Overall, the ranitidine market outlook reflects a balance between substantial demand for affordable gastrointestinal therapies and ongoing regulatory, safety, and reputational challenges. Future growth will depend on reliable impurity controls, consistent regulatory compliance, sustained product availability, and the ability of reformulated ranitidine products to regain the confidence of healthcare professionals and patients.
Key Topics Covered:
1 Introduction
1.1 Study Assumptions & Market Definition
1.2 Scope of the Study
2 Research Methodology
3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising GERD and Peptic Ulcer Burden
4.2.2 Preference for Low-Cost Acid Suppression in Price-Sensitive Markets
4.2.3 Established Oral Dosage Familiarity in Hospital and Retail Formularies
4.2.4 Reformulated Products and Impurity-Control Capabilities Reopening Selected Demand Pools
4.2.5 Pediatric and Geriatric Liquid-Dosing Needs in Selected Care Settings
4.2.6 Short-Course Procurement Preference in Acute Care and Stock-Buffering by Buyers
4.3 Market Restraints
4.3.1 NDMA Recall Legacy and Persistent Trust Deficit
4.3.2 Substitution by PPIs and Famotidine-Based Alternatives
4.3.3 Compliance, Testing, and Batch-Release Cost Burden
4.3.4 Stability, Packaging, and Cold-Chain Sensitivity in Reformulated Supply
4.4 Value / Supply-Chain Analysis
4.5 Regulatory Landscape
4.6 Technological Outlook
4.7 Porter's Five Forces Analysis
4.7.1 Threat of New Entrants
4.7.2 Bargaining Power of Suppliers
4.7.3 Bargaining Power of Buyers
4.7.4 Threat of Substitutes
4.7.5 Industry Rivalry
5 Market Size & Growth Forecasts
5.1 By Strength
5.1.1 75 mg
5.1.2 150 mg
5.1.3 300 mg
5.2 By Form
5.2.1 Tablet
5.2.2 Syrup
5.2.3 Injection
5.3 By Route of Administration
5.3.1 Oral
5.3.2 Intravenous
5.4 By Application
5.4.1 Gastroesophageal Reflux Disease
5.4.2 Peptic Ulcer Disease
5.4.3 Zollinger-Ellison Syndrome
5.4.4 Erosive Esophagitis
5.4.5 Stress Ulcer Prophylaxis
5.5 By Distribution Channel
5.5.1 Hospital Pharmacies
5.5.2 Retail Pharmacies
5.5.3 Online Pharmacies
5.6 By End User
5.6.1 Hospitals
5.6.2 Clinics
5.6.3 Ambulatory Surgical Centers
5.6.4 Home Care Settings
5.7 By Geography
5.7.1 North America
5.7.1.1 United States
5.7.1.2 Canada
5.7.1.3 Mexico
5.7.2 Europe
5.7.2.1 Germany
5.7.2.2 United Kingdom
5.7.2.3 France
5.7.2.4 Italy
5.7.2.5 Spain
5.7.2.6 Rest of Europe
5.7.3 Asia-Pacific
5.7.3.1 China
5.7.3.2 Japan
5.7.3.3 India
5.7.3.4 Australia
5.7.3.5 South Korea
5.7.3.6 Rest of Asia-Pacific
5.7.4 Middle East & Africa
5.7.4.1 GCC
5.7.4.2 South Africa
5.7.4.3 Rest of Middle East & Africa
5.7.5 South America
5.7.5.1 Brazil
5.7.5.2 Argentina
5.7.5.3 Rest of South America
6 Competitive Landscape
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles (includes Global Level Overview, Market-level Overview, Core Segments, Financials, Strategic Information, Market Rank/Share, Products & Services, Recent Developments)
6.3.1 Apotex Inc.
6.3.2 Aurobindo Pharma Limited
6.3.3 Boehringer Ingelheim International GmbH
6.3.4 Cipla Limited
6.3.5 Dr. Reddy's Laboratories Ltd.
6.3.6 GlaxoSmithKline plc
6.3.7 Glenmark Pharmaceuticals Limited
6.3.8 Granules India Limited
6.3.9 Hikma Pharmaceuticals PLC
6.3.10 J B Chemicals and Pharmaceuticals Limited
6.3.11 Lupin Limited
6.3.12 Merck KGaA
6.3.13 Sanofi
6.3.14 Sandoz Group AG
6.3.15 Strides Pharma Science Limited
6.3.16 Sun Pharmaceutical Industries Limited
6.3.17 Teva Pharmaceutical Industries Ltd.
6.3.18 Tocris Bioscience
6.3.19 Viatris Inc.
6.3.20 Zydus Lifesciences Limited
7 Market Opportunities & Future Outlook
7.1 White-space & Unmet-need Assessment
For more information about this report visit https://www.researchandmarkets.com/r/r6al7u
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.